Cellmid
- Short interest
- 0.02%
- −0.07 pp 30d
- as of 8 Dec 2017
- Reported shorts
- 13.3K
- Shares on issue
- 53.423M
Cellmid (CDY) Short Interest
Cellmid (ASX:CDY) had 0.02% of shares reported as short positions as of 8 Dec 2017, representing 13,278 shares. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Cellmid
Cellmid is an Australian life sciences company primarily focused on developing and commercialising innovative therapies for cancer and inflammatory diseases, with its lead drug candidate being midkine. While historically involved in consumer health products, the company is currently divesting these assets to concentrate on its midkine therapeutic pipeline. Its unique value proposition lies in targeting midkine, a novel therapeutic target with potential applications across multiple disease areas.
Company profile →Cellmid (ASX:CDY) has 0.02% of its shares on issue reported as short positions as of 8 Dec 2017, or about 13,278 shares. Over the past 30 days that figure has fallen 0.07 percentage points, and over 90 days it has fallen 0.07 percentage points. Its highest recorded short interest was 0.09% in December 2016. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Company details
website
Be the first to discuss CDY
Start a research thread or post the first pulse update